Seeking Alpha
View as an RSS Feed

R.G.Analytics  

View R.G.Analytics' Comments BY TICKER:
Latest  |  Highest rated
  • Applicability Of Short Squeezes Of 4 Pharma Stocks [View article]
    I respect your opinion. I had no idea the article would have this kind of impact which people tell me it had and the stock price shows. There was no other news released that day. So it's not about blind belief at all. It's just observation of facts which seem to correlate, at least on the face of it. There may of course be hidden streams of cause and effect. Someone might have known of the EU news but that would be insider trading. My article had no insider info because I do not have insider info!
    Mar 31, 2012. 06:31 PM | Likes Like |Link to Comment
  • Applicability Of Short Squeezes Of 4 Pharma Stocks [View article]
    1) Your selective quoting to back up your faulty logic is typical of the basher you're known to be. It was well received for a variety of reasons which you chose to ignore, such as the many emails of appreciation I received and other media articles which quoted it and other reasons.

    2) The patients and doctors I quoted are real people -- how I know that is my business but you can remain in ignorance. I know bashers / 25+M shorts like to remain in denial.

    3) A short squeeze doesn't need a surprise positive event. The people you try to protect are sitting on the stock like a bunch of elephants in a room. Imagine them all running for the door. This is what happened to ARNA -- no significant news - just a small SA article and probably one elephant got freaked and a few tried to get out.

    4) Whether a news qualifies or not doesn't matter because no major event is needed for a short squeeze. It can happen any day any time when there are so many shorts sitting on a stock based on illusive reasons -- if they had a good reason that danger was not there but in case of AVNR as in ARNA they were just in denial. Your kind of mentality.

    5) Sure, "Europe doesn't qualify, partner doesn't qualify". This coming from a well known basher is no surprise.

    6) A short squeeze will happen. I never said when. It's a matter of when not if. I have patience. Time is on the side of longs and not shorts.
    Mar 31, 2012. 02:14 AM | 1 Like Like |Link to Comment
  • Applicability Of Short Squeezes Of 4 Pharma Stocks [View article]
    That's what others say. I got several emails from people who saw correlation between that article and the price surge. The Europe news had not come out at that point or anytime that day.
    Mar 31, 2012. 01:58 AM | Likes Like |Link to Comment
  • Applicability Of Short Squeezes Of 4 Pharma Stocks [View article]
    In My Opinion:

    1) Generally speaking, the problem I have with any short is "short and distort". Can you call Shkreli's discussion of Avanir's patents distortion or not is each person's own interpretation but most of the people I respect who looked at the case disagreed with Shkreli's interpretation and concluded Avanir's patents are strong.

    2) Nuedexta has many applications.
    3) Awareness of doctors are constantly increasing.
    4) I support their current strategy and think we can see rapid growth.

    Do your own research.
    Mar 30, 2012. 02:34 PM | Likes Like |Link to Comment
  • Analyzing Wednesday's Noteworthy Insider Buys And Sells In Healthcare And Tech [View article]
    What planet are you from? Please show us some evidence that

    Avanir markets "FazaClo for severely ill schizophrenic patients"
    Mar 8, 2012. 06:31 PM | Likes Like |Link to Comment
  • 3 Biotech Companies: 2 To Buy And 1 To Day Trade [View article]
    << "(on label)" neuropathic pain sales are years away. >>

    Off label use is very common in neurology. Many doctors won't wait for approval specially as the trial supports the already positive reported results.

    << As far as your snap judgement on my character...
    I guess I didn't realize that if I thought a short-term trade on a particular stock was a good strategy it rendered me devoid of character. >>

    A flip flopper whose opinion is only formed not according to facts (which have not changed since he turned from a basher to a pumper and back) but to suit his trades, is not a good character, in my book.
    Mar 4, 2012. 12:47 PM | Likes Like |Link to Comment
  • Avanir: Addressing The Strength Of Nuedexta's Patents; Imminent Short Squeeze [View article]
    This article is not about whether Nuedexta is a block buster or not. It doesn't need to be to help a lot of people and Avanir alike. Your comment that it's a fluff is just disparaging the company which is not surprising given 26 Million shorted shares which will cause a painful short squeeze and boost the stock price up, IMO.
    Mar 2, 2012. 02:06 PM | Likes Like |Link to Comment
  • Avanir: Addressing The Strength Of Nuedexta's Patents; Imminent Short Squeeze [View article]
    With 26 Million shorted shares, no warrants, no other way out, and institutions scooping up shares, I'm not at all surprised to see these bashers spreading fear uncertainty and doubt about Avanir to get people to sell.

    << if the case is so "frivolous" that you didn't even bother to include it in your first article under the "bear case" >>

    Because even shorts know it's a frivolous case!!

    << why doesn't Avanir seek a summary judgement
    to get it thrown out with prejudice?
    How about petitioning a judge to get an injunction against the generic drug makers? >>

    You really want an answer to that stupid question Rayonman? Check with your hedge fund buddies. They'll give you the answer.

    << And the generic drug makers would not file these patent challenges if they didn't see some chance of winning. >>

    Exactly. They're taking a chance. Every person who files a frivolous case takes a chance. Even a shot in the dark has a chance.
    Mar 2, 2012. 08:59 AM | Likes Like |Link to Comment
  • Avanir: Addressing The Strength Of Nuedexta's Patents; Imminent Short Squeeze [View article]
    With 26 Million shorted shares, no warrants, no other way out, and institutions scooping up shares, I'm not at all surprised to see these bashers spreading fear uncertainty and doubt about Avanir to get people to sell.

    Here goes Rayonman, a guy who regularly goes out of his way to bash Avanir:

    << There are other possible explanations like small market size>>

    PBA market size is not small. Many surveys have been done. It's a large market and it's unserved.

    << quotes from the possible effectiveness of other drugs like SSRIs >>

    SSRI's destroyed a friend of mine recently. Nuedexta works significantly better and has significantly less side effects.

    << cardiovascular risk and the expense of Nuedexta. >>

    This is an old line from the pathetic basher Rayonman trying to scare people and get them to sell their shares. FDA has deemed Nuedexta safe and there's been no reported cardiac death like Rayonman preaches about.

    << Also it is hard to believe the projected market size of PBA... "surveys" that were not done to the caliber of medical research >>

    Ok now the pathetic puppet of short interest is accusing Avanir of having cooked up some phony survey (notice the quotes he put around surveys.

    << in my opinion>>

    Now he's trying to cover his behind after having accused the company of doing a phony survey. You can't publish that X is an alcoholic when he is not, and then say, "In my opinion".

    26 Million shorted shares. No way out except open market purchase. Short squeeze.
    Mar 2, 2012. 08:53 AM | Likes Like |Link to Comment
  • Avanir: Addressing The Strength Of Nuedexta's Patents; Imminent Short Squeeze [View article]
    You're a joke. Taking a drug to market sometimes costs one billion dollars. That's not the issue. The issue is you guys are stuck in cement with a 26 million share short position. No warrants, no sizeable calls, company has made it clear it has many choices other than dilution IF it ever needs funds (it may never), and sales growing. IMO, Shorts are and should be extremely worried.
    Mar 1, 2012. 04:47 PM | Likes Like |Link to Comment
  • Avanir: Addressing The Strength Of Nuedexta's Patents; Imminent Short Squeeze [View article]
    Good point Andy. Thanks for all your positive contributions here and on other forums. I've learned a lot from you.
    Mar 1, 2012. 01:28 PM | Likes Like |Link to Comment
  • Avanir: Addressing The Strength Of Nuedexta's Patents; Imminent Short Squeeze [View article]
    The cockroaches are out already. It just shows how terrified the 26 Million short interest is. Yesterday's news was spectacular.
    Mar 1, 2012. 01:27 PM | Likes Like |Link to Comment
  • Avanir: Addressing The Strength Of Nuedexta's Patents; Imminent Short Squeeze [View article]
    You're welcome. I believe shorts have put up a psychological war because they need to cover 26 Million shares. Institutions have been increasing their holding. Company has said it has many other options than to dilute if and when it needs funding (and that's a big if), and no call options of significant size is available. So retail is the only hope these shorts have to shake off shares from, and that explains the relentless bashing and spread of FUD and misinformation. Fortunately for us shareholders the argument of shorts is extremely weak. Look at their logic: because there's a shelf registration they're concluding that new shares will be registered. I think the company is determined to make shorts lose their shorts.
    Mar 1, 2012. 01:25 PM | Likes Like |Link to Comment
  • Avanir: Addressing The Strength Of Nuedexta's Patents; Imminent Short Squeeze [View article]
    With 26 Million shorted shares, no warrants, no sizeable call options, many alternative or no need for dilution, opposition to positive facts about Avanir is not at all surprising.
    Mar 1, 2012. 10:05 AM | 1 Like Like |Link to Comment
  • 3 Biotech Companies: 2 To Buy And 1 To Day Trade [View article]
    You won't have much of a chance trading AVNR. Unless you're connected to the large short interest you're up against that competition which has clearly shown it wants to cover and needs to buy 26 Million shares in the open market and nowhere else as there are no warrants and no options of any significance. You're also up against institutions who've clearly shown they have an appetite for more shares of AVNR. So your recommendation is foolish at best.

    You're also wrong about neuropathic pain revenue being years away. You're also completely ignoring other catalysts. It's your choice to wait, and you may gain a couple of pennies here and there in day trading but the significant gains with this stock comes with locking in a substantial number of shares while they're still so grossly undervalued and hanging on to it (not trade it). If you sell it there's no guarantee you can buy it back without a loss (reasons stated above).

    The problem with people like you is you have no character. You flip flop and your values changes based on your trades.
    Feb 28, 2012. 07:02 PM | Likes Like |Link to Comment
COMMENTS STATS
45 Comments
17 Likes